Oxford Global's Pharma Open Innovation Symposium
7 June 2010, Switzerland
Osney Media Limited

Registered office: Curzon House, 24 High Street, Banstead, Surrey, SM7 2LJ
Registered in England No: 3079922
VAT number GB 662 4441 42
Solution Providers

The event will be analysing the Critical Importance of Open Innovation within the Pharmaceutical Industry. This event takes place before our 11th Annual Drug Discovery Leaders Summit (http://www.drugdiscovery-summit.com) which will take place on the 9th -10th June 2010. By

sponsoring the Open Innovation symposium also means that you can attend the 2nd and 3rd day and take advantage of meeting the senior R&D leaders of the pharma industry.

 

Over the day, the open innovation event and the Drug Discovery Summit attracts over 200 senior attendees working in international business development, external collaboration, open innovation,

research & development and knowledge management from leading pharmaceutical, biotechnology, companies as well as academic institutions in UK, Europe and the US. The programme covers insights from leading influential thinkers on the benefits of Open Innovation (OI) including their views on topics such as IP & collaboration Issues whilst discussing the value Open Innovation can bring

to Pharmaceutical R&D.

 

Key topic areas that will be explored include:-

·       Business Models

·       IP and Collaboration Issues

·       Academia Open Innovation

·       Biopharma Open Innovation

·       Current Open Innovation Initiative and Case Studies

·       Lessons learned from outside Pharma

 

Key speakers on the first day include:

·      Thomas Senderovitz, Senior Vice President Global Development, Grunenthal

·      Philip Oliver, Associate Director for Global External R&D Europe, Eli Lilly

·      Giuseppe Ciaramella, Executive Director, Head of Biotherapeutics, Sandwich, Pfizer

·      Chas Bountra, Chief Scientist, University of Oxford, Structural Genomics Consortium

·      Peter Luke, Senior Director, Worldwide Business Development (Strategic Alliances), Pfizer

·      Patrice Talaga, Director, Chemistry Outsourcing, UCB

·      Jason Swedlow, Professor of Quantitative Cell Biology Wellcome Trust Centre for Gene Regulation& Expression, College of Life Sciences, University of Dundee

·      Rob Cooke, Director, Science Environment Development, GSK

 

On the 2nd and 3rd day, the key speakers include:

·          Andrew von Eschenbach, Senior Advisor, Greenleaf Health

·          Michel Pairet, Corporate Senior Vice President, Research, Boehringer Ingelheim

·          Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GlaxoSmithKline

·          Stephen Friend, President, CEO and a Co-Founder, Sage Bionetworks

·          Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen

·          Nick Terrett, Chief Scientific Officer, Ensemble Discovery Corporation

·          Søren Bregenholt, COO, Symphogen

·          Rob Hayes, CSO, CENTYREX a J&J Internal Venture 

·          Steve Hunt III, Senior Vice President, Discovery Research, Ascent Therapeutics

·          John Desjarlais, Vice President, Research, Xencor

·          Andrew Hopkins, Research Professor of Translational Biology & Chair of Medicinal Informatics Division of Biological Chemistry and Drug Discovery College of Life Sciences University of Dundee

·          Jeremy Everett, Vice President, Research Centres of Emphasis, Sandwich, Pfizer

·          Ben Askew, Vice President Research, Head of NCE Technologies, EMD Serono Research Institute

·          Jutta Heim, Chief Technology Officer, Evolva SA

·          Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, Head of

           Strategic Modeling and Simulation, Bristol Myers Squibb

·          Andreas Sewing, Research Fellow / Director, Primary Pharmacology Unit, Pfizer

·          Salvatore Alesci, Senior Director & Head, Translational Immunology, Pfizer

·          John Overington, Team Leader, Chemogenomics, EMBL – European Bioinformatics Institute, EMBL-EBI

·          Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer

·          Craig Johnstone, Value Chain Leader, RA-CVGI, AstraZeneca

·          Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson

·          Marjoleen Nijsen, Head Preclinical PK/PD, Abbott GmbH & Co. KG, Germany

·          Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative Technology Centre, Department of Chemistry, Cambridge University

·          Birgit Schoeberl, Vice President of Discovery, Merrimack Pharmaceuticals

 

 

Achieve your business objectives in the most time efficient manner through:

·       Exhibit and meet with your potential customers

·         Network with customers through sponsoring hosted drinks reception and luncheon/dinner

·         Educate customers and potential customers about your products and services through presenting a speech for 30 minutes and/or conducting a one hour workshop

If you would like to receive more information on sponsorship and attendance, please contact sponsorship@oxfordglobal.co.uk

 

 

Sponsors:
Home |  |  |  | Speakers |  | Solution Providers | Delegates | Media Partners | Venue | Organisers | Other Events | Contact | 
© Oxford Global's Pharma Open Innovation Symposium